(Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure

1. An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure, comprising an effective amount of a compound according to Formula (I), or a pharmaceutically acceptable salt thereof:

wherein Y is

and wherein

R1, R9 independently=H, alkyl, amino, alkenyl, alkoxy, aryl;

R2, R3, R4, R7 independently=H, alkyl, halogen, amino, hydroxyl, cyano, alkoxy;

R6=H, alkyl, halogen, hydroxyl, cyano, alkoxy

R5, R8 independently=H, alkyl, alkyl substituted with amine, alkyl substituted with hydroxyl, (C═O)R1, (C═O)OR1, (C═O)NR1, aryl;

R1 and R2 can form a 5-7 membered ring;

R5 and R6 can form a 5-7 membered ring;

R5 and R8 can form a 5-7 membered ring; and

a pharmaceutically acceptable vehicle therefore.

2. The composition of claim 1 , further comprising a compound selected from the group consisting of:

ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, gelling agents, hydrophobic bases, vehicles, buffers, sodium chloride, and water.

3. The composition of claim 1 wherein said composition comprises from about 0.01 percent weight/volume to about 5 percent weight/volume of said compound.

4. The composition of claim 1 wherein said composition comprises from about 0.25 percent weight/volume to about 2 percent weight/volume of said compound.

5. A method of controlling intraocular pressure comprising: applying a therapeutically effective amount of an ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure to the affected eye of a human or other mammal, the composition comprising an effective amount of a compound according to Formula (I), or a pharmaceutically acceptable salt thereof:

wherein Y is

and wherein

R1, R9 independently =H, alkyl, amino, alkenyl, alkoxy, aryl;

R2, R3, R4, R7 independently =H, alkyl, halogen, amino, hydroxyl, cyano, alkoxy;

R6=H, alkyl, halogen, hydroxyl, cyano, alkoxy;

R5, R8 independently=H, alkyl, alkyl substituted with amine, alkyl substituted with hydroxyl, (C═O)R1, (C═O)OR1, (C═O)NR1, aryl;

R1 and R2 can form a 5-7 membered ring;

R5 and R6 can form a 5-7 membered ring;

R5 and R8 can form a 5-7 membered ring; and

a pharmaceutically acceptable vehicle therefore.

6. The method of claim 5 , wherein said applying comprises applying 1 to 2 drops of a composition comprising from about 0.01 percent weight/volume to about 5 percent weight/volume of a compound according to Formula (I) 1 to 4 times daily.